SpringWorks Therapeutics executive sells $62,168 in stock

Ashar Bhavesh, Chief Commercial Officer at SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), recently sold 1,016 shares of the company’s common stock. The company, currently valued at $4.2 billion, has shown impressive momentum with a 37% gain over the past six months and maintains remarkable gross profit margins of 93%. The transaction, which took place on February 20, 2025, was conducted under a pre-established trading plan in compliance with Rule 10b5-1. The shares were sold at a weighted average price of $61.1891, resulting in a total transaction value of $62,168. Following this sale, Bhavesh holds 62,053 shares of SpringWorks Therapeutics. The sale was executed through multiple transactions with prices ranging from $61.15 to $61.36, near the stock’s 52-week high of $62. According to InvestingPro, analysts maintain a strong buy consensus with price targets ranging from $63 to $87, suggesting potential upside ahead. Discover 11 more exclusive ProTips and comprehensive analysis in the Pro Research Report.

In other recent news, SpringWorks Therapeutics has garnered significant attention following the FDA’s approval of their drug, GOMEKLI, for treating neurofibromatosis type 1 with symptomatic plexiform neurofibromas. This approval, which includes a rare pediatric disease priority review voucher, underscores the drug’s potential impact on the treatment landscape. The Phase 2b ReNeu trial results showed promising response rates, enhancing confidence in the drug’s efficacy. Additionally, TD Cowen analysts have raised their price target for SpringWorks to $66, maintaining a "Buy" rating, influenced by the recent FDA approval and potential European Union launch in 2025.

Merck (NSE:PROR) KGaA is in advanced discussions to acquire SpringWorks, although no final agreement has been reached. The acquisition could be valued between $6 billion and $7.5 billion, reflecting the projected sales potential of SpringWorks’ treatments. Guggenheim has also maintained a "Buy" rating on SpringWorks, albeit with a slight adjustment in the price target to $78, highlighting the company’s long-term prospects despite potential risks. These developments collectively contribute to a promising outlook for SpringWorks as it advances its pipeline and commercial strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.